Grunenthal GmbH-Product Pipeline Review-2015

Grunenthal GmbH-Product Pipeline Review-2015

  • Products Id :- GMDHC07172CDB
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Grunenthal GmbH-Product Pipeline Review-2015


Global Markets Direct's, 'Grunenthal GmbH-Product Pipeline Review-2015', provides an overview of the Grunenthal GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Grunenthal GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Grunenthal GmbH including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Grunenthal GmbH's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Grunenthal GmbH's pipeline products

Reasons To Buy

Evaluate Grunenthal GmbH's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Grunenthal GmbH in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Grunenthal GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Grunenthal GmbH and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Grunenthal GmbH

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Grunenthal GmbH and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Grunenthal GmbH Snapshot 6

Grunenthal GmbH Overview 6

Key Information 6

Key Facts 6

Grunenthal GmbH-Research and Development Overview 7

Key Therapeutic Areas 7

Grunenthal GmbH-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Partnered Products 12

Partnered Products/Combination Treatment Modalities 13

Grunenthal GmbH-Pipeline Products Glance 14

Grunenthal GmbH-Late Stage Pipeline Products 14

Phase III Products/Combination Treatment Modalities 14

Grunenthal GmbH-Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Grunenthal GmbH-Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Grunenthal GmbH-Unknown Stage Pipeline Products 19

Unknown Products/Combination Treatment Modalities 19

Grunenthal GmbH-Drug Profiles 20

cebranopadol 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

tapentadol hydrochloride 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Small Molecule 1 for Pain 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Small Molecule 2 for Pain 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

GRTTA-2210 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

RO-656570 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecule-3 for Pain 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecules for Inflammation 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Small Molecules to Block TRPV1 for Chronic and Neuropathic Pain 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Small Molecule for Pain 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Small Molecules to Activate KCNQ Channels for Chronic Pain and CNS disorder 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

lexanopadol 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Small Molecules to Target KCNQ and TSPO for Pain 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Grunenthal GmbH-Pipeline Analysis 36

Grunenthal GmbH-Pipeline Products by Target 36

Grunenthal GmbH-Pipeline Products by Route of Administration 37

Grunenthal GmbH-Pipeline Products by Molecule Type 38

Grunenthal GmbH-Pipeline Products by Mechanism of Action 39

Grunenthal GmbH-Recent Pipeline Updates 40

Grunenthal GmbH-Dormant Projects 42

Grunenthal GmbH-Company Statement 43

Grunenthal GmbH-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Tables

Grunenthal GmbH, Key Information 6

Grunenthal GmbH, Key Facts 6

Grunenthal GmbH-Pipeline by Indication, 2015 8

Grunenthal GmbH-Pipeline by Stage of Development, 2015 10

Grunenthal GmbH-Monotherapy Products in Pipeline, 2015 11

Grunenthal GmbH-Partnered Products in Pipeline, 2015 12

Grunenthal GmbH-Partnered Products/ Combination Treatment Modalities, 2015 13

Grunenthal GmbH-Phase III, 2015 14

Grunenthal GmbH-Phase II, 2015 15

Grunenthal GmbH-Phase I, 2015 16

Grunenthal GmbH-Preclinical, 2015 17

Grunenthal GmbH-Discovery, 2015 18

Grunenthal GmbH-Unknown, 2015 19

Grunenthal GmbH-Pipeline by Target, 2015 36

Grunenthal GmbH-Pipeline by Route of Administration, 2015 37

Grunenthal GmbH-Pipeline by Molecule Type, 2015 38

Grunenthal GmbH-Pipeline Products by Mechanism of Action, 2015 39

Grunenthal GmbH-Recent Pipeline Updates, 2015 40

Grunenthal GmbH-Dormant Developmental Projects,2015 42

Grunenthal GmbH, Other Locations 44

Grunenthal GmbH, Subsidiaries 45

List of Figures

Grunenthal GmbH-Pipeline by Top 10 Indication, 2015 8

Grunenthal GmbH-Pipeline by Stage of Development, 2015 10

Grunenthal GmbH-Monotherapy Products in Pipeline, 2015 11

Grunenthal GmbH-Pipeline by Top 10 Target, 2015 36

Grunenthal GmbH-Pipeline by Top 10 Route of Administration, 2015 37

Grunenthal GmbH-Pipeline by Top 10 Molecule Type, 2015 38

Grunenthal GmbH-Pipeline Products by Top 10 Mechanism of Action, 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Grunenthal GmbH; Grunenthal GmbH - Key Therapeutics; Grunenthal GmbH - Pipeline Overview and Promising Molecules; Grunenthal GmbH - News; Grunenthal GmbH - Latest Updates; Grunenthal GmbH - Pipeline; Grunenthal GmbH - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101595
Site License
USD 3000 INR 203190
Corporate User License
USD 4500 INR 304785



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]